PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-6.78%
Negative revenue growth while 3088.T stands at 2.40%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-5.59%
Negative gross profit growth while 3088.T is at 4.34%. Joel Greenblatt would examine cost competitiveness or demand decline.
-26.75%
Negative EBIT growth while 3088.T is at 10.18%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-24.32%
Negative operating income growth while 3088.T is at 16.98%. Joel Greenblatt would press for urgent turnaround measures.
-22.82%
Negative net income growth while 3088.T stands at 13.81%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-22.81%
Negative EPS growth while 3088.T is at 15.75%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-22.81%
Negative diluted EPS growth while 3088.T is at 15.79%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.00%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.00%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
152.83%
10Y revenue/share CAGR 1.25-1.5x 3088.T's 120.29%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
51.72%
5Y revenue/share CAGR at 50-75% of 3088.T's 75.11%. Martin Whitman would worry about a lagging mid-term growth trajectory.
34.22%
3Y revenue/share CAGR under 50% of 3088.T's 93.99%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
137.62%
Below 50% of 3088.T's 421.14%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
68.73%
5Y net income/share CAGR at 50-75% of 3088.T's 110.14%. Martin Whitman might see a shortfall in operational efficiency or brand power.
25.56%
Below 50% of 3088.T's 165.69%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
310.55%
10Y equity/share CAGR 1.25-1.5x 3088.T's 240.73%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
81.59%
5Y equity/share CAGR at 50-75% of 3088.T's 132.97%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
35.06%
Below 50% of 3088.T's 105.75%. Michael Burry suspects a serious short-term disadvantage in building book value.
136.36%
Below 50% of 3088.T's 320.00%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
160.00%
5Y dividend/share CAGR above 1.5x 3088.T's 80.00%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
62.50%
3Y dividend/share CAGR at 75-90% of 3088.T's 80.00%. Bill Ackman wants overhead or revenue enhancements to match competitor's dividend growth.
3.80%
Our AR growth while 3088.T is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
8.07%
We show growth while 3088.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
0.32%
Positive asset growth while 3088.T is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
2.65%
Positive BV/share change while 3088.T is negative. John Neff sees a clear edge over a competitor losing equity.
-4.27%
We’re deleveraging while 3088.T stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-0.81%
We cut SG&A while 3088.T invests at 3.38%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.